WellBeing International

WBI Studies Repository
5-1-2010

Calling on Science: Making “Alternatives” the New Gold Standard
Melvin E. Andersen
The Hamner Institutes for Health Sciences

Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/invrmod
Part of the Bioethics and Medical Ethics Commons, Laboratory and Basic Science Research
Commons, and the Research Methods in Life Sciences Commons

Recommended Citation
Andersen, M. E. (2010). Calling on science: making “alternatives” the new gold standard. ALTEXAlternatives to animal experimentation, 27(2), 135-143. DOI https://doi.org/10.14573/altex.2010.2.135

This material is brought to you for free and open access
by WellBeing International. It has been accepted for
inclusion by an authorized administrator of the WBI
Studies Repository. For more information, please contact
wbisr-info@wellbeingintl.org.

Highlights of WC7 – part 1
Calling on Science:
Making “Alternatives” the New Gold Standard 1
Melvin E. Andersen

The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA
Summary

All of life’s great journeys start with a goal in mind! The 2007 NAS report, Toxicity Testing in the 21st
Century – A Vision and A Strategy, has proposed a clear goal. This report envisions a not-so-distant future
where all routine toxicity testing for environmental agents will be conducted in human cells in vitro evaluating perturbations of cellular responses in a suite of toxicity pathway assays. Dose response modeling would
utilize computational systems biology models of the circuitry underlying each toxicity pathway; in vitro to
in vivo extrapolations would use pharmacokinetic models, ideally physiologically based pharmacokinetic
models, to predict human blood and tissue concentrations under specific exposure conditions. Results from
these toxicity pathway assays and associated dose response modeling tools rather than those from high
dose studies in animals would represent the new gold standard for chemical risk assessment. This talk
focuses on some of the scientific challenges required to make this vision a reality, including characteristics
of assay design, prospects for mapping and modeling toxicity pathways, assay validation, and biokinetic
modeling. All of these tools necessary for this transformation of toxicity testing to an in vitro platform are
either available or in advanced development. Science must lead the transformation. The scientific community, animal alternatives groups, regulatory agencies, and funding organizations will also have to muster
the resolve to work together to make this vision a reality.
Keywords: gold standard, toxicity pathways, in vitro biology, computational systems biology, toxicity testing
transformation
1 Introduction

This year marks the 50th anniversary of the publication of The
Principles of Humane Experimental Technique by William Russell and Rex Burch. Their contribution focused attention on the
3Rs – replacement, reduction, and refinement. In toxicity testing,
the primary initiative with the 3Rs in the intervening decades
has arguably focused on reduction of animal usage while holding
firm the belief that results from animal studies provide a “Gold
Standard” for making decisions about possible human health
risks of compounds. The very wording, “alternatives”, has often
been regarded by many in toxicology as those test methods that
will reduce animal usage even though the result from the tests
are not necessarily optimal for risk assessment decision-making.
A second challenge in reduction of animal use through mechanistically-based testing arises from the idea of validating “alternatives”. The process of validation with alternatives, in general,
focuses on the ability of a test or a series of tests to give results
consistent with those that would be obtained through testing in
animals. In this context, all alternatives will fall short of the mark

of complete concordance with in vivo outcomes. Are all efforts
to reduce animal use significantly doomed to disaster as they are
dashed against the “gold standard” barrier?
The recommendations of a recent report (NRC, 2007) from
the US National Academy of Sciences, Toxicity Testing in the
21st Century: A Vision and A Strategy argues that it is time to
redefine the toxicity testing paradigm, moving away from high
dose studies in animals to in vitro assays assessing perturbations of toxicity pathways by environmental agents. In essence,
the report supports a sweeping redefinition of our “gold standard.” The author of this present paper was a member of the NAS
toxicity testing committee. Since the publication of the NAS
report in June 2007, several of the NAS committee members
have presented aspects of the report at more than 40 venues in
North America and Europe. These presentations and the lively
debate engendered on these occasions have sharpened ideas
about the use of results from in vitro toxicity pathway assays in
risk or safety assessments. The NAS report, although published
in 2007, was essentially completed in fall 2006. Advances in
several key technologies in the past three years – especially

1 Several of the ideas in the introductory portion of this paper reflect those from two previous contributions (Krewski et al.,
2009; Andersen and Krewski, 2009). The interested reader should also consult these two papers.
Plenary lecture held at the 7 th Worldcongress in Rome 2009
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stem cell biology, computational systems biology, and pathway
mapping and modeling – appear likely to be key catalysts for
moving the vision forward. Finally, the transformation from
current, traditional approaches to new in vitro methods based
on human biology will not come easily. Who will step up to assist in the transformation to a new approach to testing and risk
assessment? Several initiatives within the United States, both
in federal government research organizations and in the private
sector, look likely to accelerate implementation. These topics –
(1) the recommendations from the NAS report, (2) the manner
in which the in vitro toxicity pathway data can be organized for
risk/safety assessments, (3) the call to the alternatives community to embrace 21st century computational and bioinformatics
methodologies in designing and interpreting in vitro results, and
(4) the institutional opportunities to accelerate implementation
of the NAS vision – are discussed in turn in this current paper.
2 Toxicity Testing in the 21st Century:
a Vision and a Strategy

The US Environmental Protection Agency and the US National
Institute of Environmental Health Sciences asked the US National Research Council (NRC) to provide guidance on new
directions in toxicity testing, incorporating emerging technologies such as genomics and computational systems biology into
a new vision for toxicity testing. In 2004, the NRC convened
a 22 person committee for this purpose (Tab. 1). The committee produced two reports. The committee’s interim report (NRC,
2006) provided an overview of testing methods and approaches
that could incrementally improve traditional toxicity testing.
This report noted that health protection agencies and the public
had experienced increasing frustration with the failure of current approaches to toxicity testing to provide timely, relevant
information to support informed regulation of environmental
agents. These toxicity testing strategies relied primarily on the
observation of adverse health responses in laboratory animals
treated with high doses of these agents. Estimating risks to human populations based on high dose animal studies require difficult extrapolations, first from high doses to environmental levels
that are usually orders-of-magnitude lower than those used in
the animal studies, and then from animals to humans. These traditional toxicity testing approaches and methods for their interpretation date back some 30 to 60 years, and were developed at
a time when knowledge of biology – and of the manner in which
chemical exposures perturbed biological processes – was primitive. While there have been steady, incremental improvements in
toxicity testing over the years, there has been no comprehensive
evaluation of the manner in which advances in cellular and molecular biology might improve toxicity testing practices.
The final report of the toxicity testing committee (NRC, 2007)
outlined design criteria that needed to be considered in any
revisions of practices for toxicity testing. In choosing among
various toxicity testing options, four criteria are important: (1)
achieving broad coverage of chemicals, chemical mixtures, outcomes, and life stages, (2) reducing the cost and time required
for toxicity testing, (3) developing a better scientific basis for
136

assessing human health effects of environmental chemicals,
including knowledge of modes of action, and (4) minimizing
use of animals in testing. The consideration of how these criteria should guide a modern approach to toxicity testing led the
committee to propose a new framework for toxicity testing that
would entail a major overhaul of current practice.
Toxicity testing and targeted in life studies
The NAS committee vision consisted of several key technology
areas (Fig. 1). While also including in silico methods for assessing structure activity relationships and population assessments,
the transformative parts of their new toxicity testing paradigm
was the types of toxicity testing and the manner in which results
from these tests could be organized to support human health
risk assessment. This vision centers on defining dose-response
relationships for toxicity pathway perturbations that would be
expected to lead to adverse health outcomes if the perturbations
were maintained in vivo at a sufficient level of intensity and for
a sufficient duration of exposure. The key component of the vision is assaying perturbations of toxicity pathways, which are
simply normal biological signalling pathways that may be perturbed by chemical exposures. Toxicity pathway testing would
require a suite of in vitro tests that could identify the range of
significant perturbations of human pathways that might occur as
Tab. 1: The Roster of the NRC Toxicity Testing Committee
Daniel Krewski (Chair), University of Ottawa, Ottawa, ON
Daniel Acosta, Jr., University of Cincinnati, Cincinnati, OH
Melvin Andersen, The Hamner Institutes for Health Sciences,
Research Triangle Park, NC
Henry Anderson, Wisconsin Division of Public Health, Madison, WI
John Bailar III, University of Chicago, Chicago, IL
Kim Boekelheide, Brown University, Providence, RI
Robert Brent, Thomas Jefferson University, Wilmington, DE
Gail Charnley, HealthRisk Strategies, Washington, DC
Vivian Cheung, University of Pennsylvania, Philadelphia, PA
Sidney Green, Howard University, Washington, DC
Karl Kelsey, Harvard University, Boston, MA
Nancy Kerkvliet, Oregon State University, Corvallis, OR
Abby Li, Exponent, Inc., San Francisco, CA
Lawrence McCray, Massachusetts Institute of Technology,
Cambridge MA
Otto Meyer, Danish Institute for Food and Veterinary Research,
Søborg, Denmark
D. Reid Patterson, Reid Patterson Consulting, Inc., Grayslake, IL
William Pennie, Pfizer, Inc., Groton, CT
Robert Scala, Exxon Biomedical Sciences (Ret.), Tucson, AZ
Gina Solomon, Natural Resources Defense Council,
San Francisco, CA
Martin Stephens, The Humane Society of the United States,
Washington, DC
James Yager, Jr., Johns Hopkins University, Baltimore, MD
Lauren Zeise, California Environmental Protection Agency,
Oakland, CA
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with human cells would markedly reduce the need for whole
animal testing, and provide much stronger, mechanisticallybased tools for human health safety assessment. It was recognized that the conversion to an in vitro basis had challenges and
the committee also suggested that targeted in vitro testing was
also likely to continue for some time where such studies could
provide information about metabolism, possible metabolite toxicity, toxicity pathways, etc. Metabolism has been recognized as
a particular challenge for developing in vitro testing alternatives
(Coecke et al., 2006).

Fig. 1: Components of the vision for Toxicity Testing in the
21st Century (NRC, 2007).
The key elements in this proposal are related to Toxicity Testing,
which includes the types of in vitro tests and short term
in vivo tests to evaluate perturbations on toxicity pathways, and
Dose-Response and Extrapolation Modeling, which provides
the requisite tools for interpreting toxicity testing results for
assessing human health risk assessment. Reproduced from
the NRC report (NRC, 2007) with permission.

a result of chemical exposure (Fig. 2). Biologic responses are
viewed as results of an intersection of exposure and biologic
function. The intersection results in perturbation of biologic
pathways. The circuitry affected by the chemical is expected to
determine shapes of dose response relationships for these perturbations. Ideally, these assays would be conducted in human
cells, cell lines or in engineered human tissues. The committee
believed that the use of a comprehensive array of in vitro tests

Dose-response and extrapolation modeling
How will results from a comprehensive suite of toxicity pathways inform quantitative risk/safety assessments for environmental agents? In this new toxicity testing strategy, in vitro
concentration response curve would cover multiple orders of
magnitude (Inglese et al., 2006, 2007) and evaluate responses
in cells/tissues from humans, the species of primary interest.
The broad range of concentrations permit the definition of dose
ranges resulting, or not resulting, in significant alterations of
normal biological function. While low dose and interspecies extrapolations are not as problematic, new challenges arise in understanding the mechanistic bases for dose-response behaviors
of the toxicity pathway assays, in calibrating expected blood/
tissue concentrations in humans against the vitro concentrations
used in the toxicity pathway assays, and in understanding the
linkages of early perturbations to adverse responses expected in
exposed people. The report identified key technologies that will
assist dose response and in vitro-in vivo extrapolations, including (1) empirical dose-response models based on results from
the in vitro, mechanistically based toxicity pathway assays, (2)
mechanistic dose-response models based on knowledge of toxicity pathway circuitry and dynamics of pathway function, and

Fig. 1: Number of animals used for experiments in Germany (until 2000) and for animal experiments and other scientific
purposes (since 2000).
tg = transgenic, WT = wild type. (Courtesy of Prof. Dr. Rainer Nobiling)
Altex 27, 2/10
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(3) physiologically based pharmacokinetic (PBPK) models to
equate tissue-media concentrations with tissue dose in exposed
people. Two recent perspectives on the NAS report provide
good overviews of the report and directions for implementation
(Krewski et al., 2009; Andersen and Krewski, 2009).
3 The new gold standard in practice

Over the past three years, there has been continuing discussions
about the NAS report with diverse stakeholder audiences. During these discussions, many questions were directed at the manner in which the pieces of the new test paradigm would integrate
together to provide quantitative approaches for risk or safety
assessment. The NAS report did outline two hypothetical cases
of “assessments” that might arise from a battery of in vitro test
using examples of a reactive gas and of a compound with estrogenic activity. These examples were cursorily developed, but
indicated how various parts of the testing and analysis would
likely contribute to health assessments. It is possible today to
provide a more complete picture of how these pieces might be
integrated (Fig. 3).
The core component of the testing will be the suite of toxicity
pathway assays (Fig. 3; section i). These assays would be developed for human cells, human cells in culture, or human three-dimensional tissue surrogates. The toxicity test assays themselves
need to be capable of evaluating the progression from initial

activation of the pathway on through degrees of perturbation
that would be considered sufficiently large to be associated with
likely toxicity if maintained over a period of time in an intact organism. For most, if not all assays, concentrations are expected
to range from sub-threshold through those causing initial pathway activation, on to regions of adaptation, and finally to those
causing adverse cellular consequences. To cover these various
degrees of response, each assay would likely provide different
levels of biological readout as a function of concentration and
duration of treatment.
Each pathway assay is expected to have specific dose response characteristics depending on the organization of the circuitry that determines the action of compounds on the toxicity
pathway. The dose response behaviors should arise from the
underlying biology of the circuitry. These core signaling processes include the initial signal recognition and then the larger
scale network through which the initial perturbation progresses
to generate toxicity in the test system. Computational systems
biology (Alon, 2006, 2007) provides the tools for describing
these circuits and the differential behavior of the circuits with
increasing degrees of perturbation.
The process of validating toxicity pathway assays would be to
study its behavior for positive control compounds and to extract
the network structure and network dynamics that determine
dose response. The sequential passage from sub-threshold, to
adaptive, to toxic conditions represents dose-dependent transitions in modes of action in an in vitro system. Dose-dependent

Fig. 3: Representation of the application of in vitro toxicity testing results for risk assessment.
Four components will contribute. (1) The suite of assays to provide broad coverage of possible targets and mechanisms of toxicity.
(2) The mapping and modeling tools to validate pathway architecture and provide dose-response models for risk assessment.
(3) The flexibility in assay output to evaluate networks that incrementally control target interactions, adaptive stress responses and
overt toxicity. Lastly, (4) the use of PBPK and biokinetic tools to relate in vitro concentrations with in vivo exposures.
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transitions in in vivo toxicology studies are well known (Slikker
et al., 2004a, 2004b). This type of response cascade has been described in vitro by Xiao et al. (2003) and by Nel et al. (2006) in
work on hierarchical oxidative stress. Feedback process control
and dose response have also been examined more theoretically
for anti-stress gene regulatory networks (Zhang and Andersen,
2007). Alon (2007) has provided a good overview of network
motifs in signaling pathways and in what were termed “developmental” networks. In practice, toxicity pathway characterization would optimally include standard operating procedures
(SOPs) for preparing cells, conducting specific assays, generating read-outs, and the detailed process by which the pathway
structure, circuit, and dynamics had been evaluated to support
dose-response modeling. The detailed pathway characterization
(essentially the process of validation of the pathway behavior)
would be the mainstay of dose response analyses. For the safety
assessment, primary attention would focus on pathways affected
at the lowest concentration (Fig. 3; sections ii and iii).
How do we relate concentrations affecting cells in vitro with
exposures in human populations likely to cause similar responses in an intact individual? Human biomonitoring for chemicals
in blood and excreta is becoming more widespread. In some
instances, concentrations of exogenous compounds in humans
may be available. Comparisons could be made between those
concentrations seen in exposed populations and those affecting cells in the toxicity pathways assays in order to estimate a
“margin of safety” or “margin of exposure.” This comparison
is unlikely to be possible with very many compounds. A more
general methodology would be development of biokinetic models (DeJongh et al., 1999) to determine the human exposure situations expected to give cell and tissue concentrations similar to
those affecting the human cells in the in vitro pathway assay test
(Fig. 3; iv). These approaches are extensions of the physiologically based pharmacokinetic types of models that have been of
interest both with toxic substances and pharmaceuticals (Reddy
et al., 2005; Bouvier d’Yvoire et al., 2007). A coordinated effort
is required to develop a larger suite of PBPK models and to enhance efforts in reverse dosimetry, i.e., estimating the exposure
levels in a human population that produce specific blood/tissue
concentrations (Clewell et al., 2008). Current efforts to improve
dosimetry methods are also advancing in vitro-in vivo extrapolation tools (Gulden and Seibert, 2003; Heringa et al., 2004).
The risk assessment process would entail running the suite of
assays for a compound to see the pattern of activation of pathways and the concentrations at which effects were noted in various pathway assays. The most sensitive hits from the suite of
assays would then be organized to support both dose response
modeling and in vitro-in vivo extrapolation. The pattern of activity across the suite of assays could also provide signatures to
indicate the types of toxic endpoints that might be observed in
vivo (Dix et al., 2007). For example, specific signatures might
indicate a high likelihood of reproductive toxicity or of hepatic
toxicity in a qualitative manner.
Risk assessments completed based on results from these toxicity pathway assays are likely to be quite different from those
arising from current approaches. Today, we see effects in animals, usually at fairly high doses, and estimate the likely inciAltex 27, 2/10

dence of response at lower doses in exposed populations. For
cancer, we might try to estimate the expected concentration
estimated to give a 1/1,000,000 level of population risk. This
process has two less than desirable outcomes – first, labeling
compounds based on high dose hazard studies and (2) providing a false sense of precision regarding our ability to extrapolate across doses and species. For instance, if Compound A
causes cancer, at a maximally tolerated dose, it becomes labeled
as carcinogen regardless of considerations of exposure levels.
Secondly, the public is led to believe that the estimates of the
low dose extrapolations are scientifically valid without any appreciation of the uncertainties about these estimates. In contrast,
the assessments based on the in vitro toxicity pathway assays
would be more directed at safety assessment, estimating regions
of exposure where no appreciable perturbations are expected in
human cells or human tissues in culture.
4 Calling on 21st century science

The NAS committee discussed a variety of key technology
areas for toxicity testing in the 21st century. While the broad
suite of new tools are likely to influence many areas of toxicology research and to greatly improve understanding of cell
signaling pathways, it is important to ask more narrowly how
specific technologies and advances will contribute to the four
components noted in Fig. 3. The three areas most likely to benefit immediately are in assay design, using stem cell technology,
pathway mapping and modeling, and computational systems biology for assessing expected dose response behaviors.
Assay design
A frequently voiced concern after publication of the report was
the difficulty in obtaining and working with primary human cells
and the caveats associated with use of human cell lines. The past
few years have provided optimism in the ability to obtain tissuespecific human and rodent stem cells from which more mature
cell types can be generated (Alonso and Fuchs, 2003). The stem
cells can be stored and grown as needed for assays and will
likely become available for a wider and wider suite of tissues
(Reya and Clever, 2005; Gaudio et al., 2009). Embryonic and
fetal amniotic fluid stem cells can be used and differentiated
through frequently tedious, multi-step processes to multiple cell
types (DeCoppi et al., 2007). With tissue-specific stem cells, the
route to mature cells is shorter and requires less manipulation
(Wang et al., 2009).
In addition to availability of tissue specific stem cells, other
advances bringing biomedical and small-scale manufacturing
processes offer opportunities to utilize human 3-dimensional
tissue in higher throughput contexts. For instance, Khetani and
Bhatia (2008) discuss the application of semiconductor manufacturing microtechnology for fabrication of microscale tissues.
A miniaturized, multiwall culture system for human liver cells
with optimized microscale architecture maintained phenotypic
functions or several weeks. These organotypic cultures could be
useful in insuring better correspondence between in vitro tests
and expected behaviors in vivo.
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A major emphasis is required to produce appropriate assays
with the right level of detail and an ability to provide appropriate read-outs across different responses levels. For risk/safety
assessments with a single compound, rapid, in vitro testing for
the suite of pathways is essential. High throughput and high data content methods were emphasized in the NAS report. In this
usage, high throughput assays allow evaluation of hundreds or
thousands of compounds across multi-point dose response in a
period of just a few days. Some assays such as the organotypic
liver assay above may not be amenable to high throughput.
For toxicity testing, it is useful to distinguish the need for high
throughput methods for testing large numbers of compounds
from efficient in vitro tests that can be done over the course of
days but may not be easily scalable to the ultra-high throughput. For evaluating the chemical space active for a particular
pathway, high throughput permits evaluation pathway perturbations for large compound libraries, leading to better in silico
modeling of structure activity relationships.
Mapping and modeling toxicity pathways
Assay outputs can be diverse as clearly evident from the US
EPA ToxCast group of assays (Dix et al., 2007). Nonetheless,
the area where the diverse array of new technologies has the
greatest possible for contribution is in mapping and modeling
the underlying signaling networks for specific toxicity pathways. The vast majority of perturbations are associated with
networks that affect transcriptional control. Such a conclusion
is obvious for so-called receptor-mediated toxicants, such as
dioxin and the aryl hydrocarbon receptor, but is equally valid
for stress response pathways. Antioxidant response signaling
starts with oxidants reacting with cellular sensors – primarily
Keap1. The modification of Keap1 leads to its dissociation
from a complex with Nrf2, allowing Nrf2 and other partnering proteins to form a promotional complex altering expression of genes controlling cellular anti-oxidants (Motohashi and
Yamamoto, 2004).
As toxicity pathway circuitry becomes better understood over
time, it will be possible to create computational systems biology models for expected dose-response relationships for each of
the assays used for toxicity testing following similar principles.
Over the past decade, tools for mapping and modeling have
blossomed. In a recent paper, Bromberg et al. (2008) described
the network by which cannabinoid receptor (CB1R) controls
neurite outgrowth. Activation of several hundred transcription
factors within the nucleus after cell stimulation was measured
to understand the logic of the signaling network. Bioinformatic
methodologies connected CB1R to 23 activated transcription
factors. Experiments with pharmacological inhibitors of kinases revealed a network organization of partial “OR” gates regulating kinases stacked above AND gates that control transcription factors. As in most instances of current research in systems
pharmacology and network modeling, the goal of these studies was not dose-response as would be a primary interest for
toxicity pathway analyses. This example provided a glimpse
of the structure of the network without attempting a quantitative computational model. The epidermal growth factor (EGF)
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signaling network is particularly well studied. Amit and colleagues (2007) used a suite of experimental and bioinformatic
tools to determine the forward signaling and feedback processes controlling the EGF network. The network was dissected
by transcriptional profiling coupled with reverse phase protein
lysate assays that assessed phosphorylation states of proteins
within the EGF pathway. The analysis provided the structure of
the logic of the circuitry for the early, immediate and later stage
portions of the network.
Computational systems biology
It appears likely that a major contribution of 21st century science will be the application of an array of technologies to elucidation, mapping and modeling the behavior of the test systems for assessing toxicity pathway dynamics. The tools would
include mRNA, transcription factor and phospho-protein time
course profiling, coupled with bioinformatic technologies to
extract network structure. The outcome would provide dynamics of the signaling networks and the dose-and time dependence of expected consequences of perturbations by test compounds, including positive controls for each of the pathways.
Dynamic behavior of signaling networks have been described
quantitatively using computational systems approaches focusing on models of transcriptional control (Alon, 2007; Aldridge
et al., 2006). Theoretical descriptions of networks leading to
better understanding of modular design elements in biological circuits have refined our vocabulary – concepts of ultrasensitivity, bistability, network gain, feedback and feed forward
motifs, noise, stochasticity, and sequential levels of early,
mid-term and late gene expression – to allow discussion of network behaviors with some commonality of terminology. These
concepts are more extensively elaborated in a course text on
“Computational Systems Biology and Dose Response” available at the Hamner Institutes web-site (http://www.thehamner.
org/education-and-training/drm_workshop.html).
5 Creating the transformational mindset

In a Figure (5-1) in Chapter 5, the NAS report discussed a
strategy for implementation, including ballpark estimates of
the time (1 to 2 decades) and costs ($ 1-2 billion) for transitioning from current animal intensive toxicity testing to a toxicity
pathway based approach. The report stressed the need for an
organization to have the lead responsibility for overseeing the
technology development to support the transition – a role that
could eventually be played by an appropriate laboratory within
the US National Institutes of Health. The overall timeline was
shown in the report in a linear fashion leading to a transition to
new approaches after completion of technology development
for assays and achieving some confidence that the suite of assays would provide adequate coverage of possible pathway
perturbations. In the current global economic climate and with
a variety of competing interests for biomedical research, is it
reasonable to expect federal agencies or the private sector to
support such a long-term, expensive initiative?
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Some aspects of the NAS vision are embedded in other programs. Three federal US agencies with responsibilities for
health-related research – the Environmental Protection Agency
(EPA), the National Institute of Environmental Health Sciences’ National Toxicology Program (NTP), and the National Institutes of Health Chemical Genomics Center (NCGC) – have a
memorandum of understanding to conduct research necessary
to advance the NRC committee vision for the future of toxicity testing. Collaboration among these organizations in the
US will be essential in establishing a national commitment to
develop the scientific foundation of the vision. This collaboration (Collins et al., 2008) focuses on research (1) to develop
high throughput test methods, (2) to identify toxicity pathways,
(3) to pursue targeted testing in short-term in vitro tests, and
(4) to develop dose-response and extrapolation models. New
approaches for in vitro toxicity testing and toxicity profiling
are key parts of several federal programs in the US (Dix et
al., 2007; National Toxicology Program, 2004). The US EPA
ToxCast program (Dix et al., 2007) is using a variety of high
throughput tests and computational methods to enhance prioritization of compounds for targeted testing in animals. A professed goal of the new interagency collaboration is predicting
high dose results in animals. Prioritization and predicting high
dose results are not part of the NAS vision. Nonetheless, the
tools and approaches being developed in this collaboration will
be important for achieving the long-term vision for transforming toxicity testing. Other tools will mature from efforts that
are today primarily focused on animal alternatives (e.g., Spielmann et al., 2000).
In the past year, the Humane Society of the United States
(HSUS) and its affiliates, the Humane Society Legislative Fund
(HSLF) and Humane Society International (HIS) have taken
steps to enlist partners to a stakeholder consortium – The Human Toxicology Project Consortium. The goal of this group is
to facilitate the global shift to a cell response pathway paradigm for chemical safety assessments. This shift, in the words
of the consortium, holds great promise for more rapid predictions of human health outcomes while superseding traditional
animal testing for environmental agents and pharmaceuticals.
The goals of this consortium is to (1) promote dialogue, information sharing and establishment of a research and development roadmap, (2) lobby for, coordinate and provide resources
to support transatlantic efforts necessary to fulfill NAS vision,
(3) engage in collaborative outreach to legislative, regulatory,
corporate, academic and public interest audiences, and (4) to
urgently develop a targeted research program to jump-start the
transformation.
This targeted research plan, focusing on proof of concept efforts, would first focus on prototype compounds and provide
examples of the application of results from toxicity pathway assays for risk/safety assessments sequentially rather than waiting
10 to 20 years to bring a totally new risk assessment paradigm
on line. The proposed research over a 5 to 10 year period would
provide examples with ten to fifteen pathway assays and generate opportunities for diverse stakeholders to gain experience in
collecting and using these results for safety assessments. The
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outline of steps for this more targeted research program includes
several components.
– Select about 10 prototypes compounds/pathway. These compounds would be chosen based on the breadth of information
about animal toxicity and of the expected toxicity pathway
targets, serving as a test bed for examining relationships between in vitro toxicity test assays and historical information
regarding in vivo results.
– Design appropriate cell-based toxicity assays. For these prototype compounds, test assay systems would focus on both
rodent and a human assay, preferentially using stem cells or
mature cells derived from these stem cells. With one or more
of the prototypes, 3-dimensional tissue systems could be used
for the assays.
– Develop the next generation quantitative risk assessment
tools. These assays would be subjected to mapping and modeling analysis to uncover pathway circuitry, the dynamics of
pathway responses to positive controls, and the dose response
behaviors expected from different levels of perturbation.
–	Examine relationships between perturbations and toxicity
for prototypes. The assay design would require consideration
of cascades that contain initial target activation, adaptive responses, and adverse responses with prolonged levels of perturbation.
– Integrate results from studies to provide representative health
risk/safety assessments. The outcome of each of the prototypes would be risk/safety assessments that would be compared to more conventional approaches from animal toxicity
data sets.
– Within the first 3-5 years expand from the first 10-prototypes
to a larger suite of pathways/compounds. This transition
should also allow some mid-course correction in the strategy, stemming from a continuing evaluation of successes and
challenges in applying the new science in assisting human
health safety assessment.
– With success in getting the program jump-started through the
consortium, other partners, including toxicity testing organizations, regulatory agencies, and federal research organizations, could be enlisted as partners in moving forward with
the transformation.
Regardless of which organization seizes leadership for the efforts to create the technology base for shifting to a new “Gold
Standard,” the central question is whether such an initiative is a
good public health investment. From the point-of-view of sparing animal use and a more humane infrastructure for testing the
answer has to be yes. Is it also likely to be a good investment
in terms of its likely scientific value? The answer here is also
a resounding yes! Our primary investment in toxicity testing
today is simply box-checking, becoming a bit more mechanistically oriented for high value chemicals that show responses
in animal toxicity tests. The in vitro, human biology approach,
elaborated here and arising from the NAS vision, has a much
reduced emphasis on rote testing and much increased emphasis
on generating detailed understanding of the signaling pathways
affected by chemicals and how perturbations/modulations in
these pathways affect biological outcome. These tools and ap-
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Fig. 4: Commonality of systems approaches to examining perturbations/modulations of normal biology for safety testing
with environmental agents, pharmaceuticals, consumer products, and foods and for drug development. SETAC: Society for
Environmental Toxicology and Chemistry.

proaches will be just as valuable in drug safety/drug development, in evaluation of safety of food and consumer products,
and in ecotoxicology (Watanabe et al., in press). In addition to
the broader applicability for human health outcomes for modulation of these pathways (Fig. 4), the organization of information on pathway structure and function is a natural post-genome
program that could provide a better understanding of health, disease and susceptibility within the human population – a much
preferred investment compared to today’s approach of in vivo
testing and the cataloging of testing results.
6 Conclusions

Toxicity testing and much of the discipline of toxicology have
reached a tipping point. Old practices focusing primarily on high
dose studies to evaluate end-organ toxicity in animals are giving
way to modern practices that assess how chemicals are likely to
affect human biology and the concentrations under which these
effects might be expected in exposed humans. This change will
not occur easily. Even though the current toxicity testing is far
from optimal, it is difficult to move away from entrenched traditional practices to a new footing. Change of this magnitude
is discomfiting for most everyone. There are, of course, serious
challenges to consider in such a transformation. They should
not be dismissed or diminished. Chemical toxicity may relate
to metabolism. How will the in vitro tests adequately assess
metabolites with new compounds undergoing in vitro screening? Which of the observed perturbations will be considered
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appropriate for the safety assessment – will it be target activation, adaptive responses, or only some clear definition of overt
toxicity in the cells? Will it be possible to describe circuitry for
most toxicity pathways in enough detail to be confident in expected dose response behaviors? Finally, where will we find the
scientists and regulators with the training and background to be
comfortable with new practices? These issues are all important,
legitimate questions that need to be considered. Yet, they should
not divert us from the goal – to move toward a redefinition of
the toxicity testing gold standard that focuses on human biology
and perturbations of human toxicity pathways in vitro. We must
bear in mind all the challenges, but push relentlessly toward the
goal of a modern approach to human safety assessment.
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